Market Herald logo


Be the first with the news that moves the market
  • Immuron’s global sales are up 54 per cent for the quarter, driven mainly by the growing success of Travelan
  • Sales of the traveller’s medication saw growth in North America and Australia, the company says this is due to new partnerships and marketing
  • In the U.S. and Canada Travelan is available online through Amazon which has been key for boosting sales
  • Immuron’s share price is remaining flat today, currently sitting at 12 cents per share

Biotech company Immuron has seen it’s North American sales grow by 111 per cent during the first quarter, reaching $269,000.

Global sales as a whole are up, recording an increase of 54 per cent on the previous year, totalling $741,000.

Immuron’s top selling product is Travelan, which helps protect users against Travellers’ Diarrhoea. According to the Centre for Disease Control and Prevention, up to 70 per cent of travellers can be affected by this.

“The sales momentum for Travelan which was already evident in fiscal year 2019 has continued strongly into the first quarter of fiscal year 2020 as consumer awareness of Travelan continues to grow,” CEO of Immuron Dr Gary Jacob said

The company attributes its growing sales in the U.S. to its programs with Passport Health Travel Clinics, Medique and Medico Mart. Through Medique, the company is selling Travelan on Amazon which is also boosting sales.

In Canada, the travel medication is sold in Shoppers Drug Mart, Jean Coutu pharmacies and online through Amazon.

In-pharmacy merchandising programs and features in catalogues lifted sales of Travelan in Australia, according to the company. Sales grew 34 per cent in the previous year throughout the quarter, accounting for over half of sales.

During September the company achieved record revenue in Australia, sales before rebates grew to $185,000.

Additionally, in August, Travelan was exhibited to over 500 general practitioners at the HealthEd Conference in Sydney.

At today’s market close, Immuron’s share price has remained the same after losing its momentary spike in early trade. Shares in the company are currently worth 12 cents each.

IMC by the numbers
More From The Market Herald
Paradigm Biopharmaceuticals (ASX:PAR) - Chief Medical Officer and Executive Director, Dr Donna Skerrett

" Paradigm Biopharmaceuticals (ASX:PAR) amends clinical trial

Paradigm Biopharmaceuticals (PAR) has made amendments to its clinical trial protocol for knee osteoarthritis treatment.
ResApp Health (ASX:RAP) - CEO & Managing Director, Dr Tony Keating

" ResApp (ASX:RAP) completes recruitment for Indian COVID-19 study

ResApp Health (RAP) has completed the recruitment ahead of schedule for its Indian COVID-19 clinical study.
Botanix Pharmaceuticals (ASX:BOT) - President & Executive Chairman, Vince Ippolito

" Botanix Pharmaceuticals (ASX:BOT) progresses clinical programs

Botanix Pharmaceuticals (BOT) progressed a number of clinical programs during the September quarter.
Recce Pharmaceuticals (ASX:RCE) - CEO, James Graham

" Recce Pharmaceuticals (ASX:RCE) receives ethics approval to begin R327 trial

Recce Pharmaceuticals (RCE) has received Human Research Ethics Committee (HREC) approval to begin its phase one intravenous (IV) trial of RECCE327 (R327).